Results 11 to 20 of about 28,829 (241)

Synergistic Interaction of Caspofungin Combined with Posaconazole against FKS Wild-Type and Mutant Candida auris Planktonic Cells and Biofilms

Antibiotics, 2022
Candida auris is a potential multidrug-resistant pathogen able to cause biofilm-associated outbreaks, where frequently indwelling devices are the source of infections.
Noémi Balla, Fruzsina Kovács, Bence Balázs, Andrew M. Borman, Aliz Bozó, Ágnes Jakab, Zoltán Tóth, Ola Kobaissi, László Majoros, Renátó Kovács   +9 more
doaj   +2 more sources

Deletion of AIF1 but not of YCA1/MCA1 protects Saccharomyces cerevisiae and Candida albicans cells from caspofungin-induced programmed cell death [PDF]

Microbial Cell, 2014
Caspofungin was the first member of a new class of antifungals called echinocandins to be approved by a drug regulatory authority. Like the other echinocandins, caspofungin blocks the synthesis of β(1,3)-D-glucan of the fungal cell wall by inhibiting the
Christopher Chin, Faith Donaghey, Katherine Helming, Morgan McCarthy, Stephen Rogers, Nicanor Austriaco   +5 more
doaj   +9 more sources

Caspofungin-induced β(1,3)-glucan exposure in Candida albicans is driven by increased chitin levels

mBio, 2023
To successfully induce disease, Candida albicans must effectively evade the host immune system. One mechanism used by C. albicans to achieve this is to mask immunogenic β(1,3)-glucan epitopes within its cell wall under an outer layer of mannosylated ...
Andrew S. Wagner, Stephen W. Lumsdaine, Mikayla M. Mangrum, Todd B. Reynolds   +3 more
doaj   +2 more sources

Caspofungin [PDF]

Reactions Weekly, 2020
An antimycotic echinocandin lipopeptide, semisynthetically derived from a fermentation product of the fungus Glarea lozoyensis. Caspofungin inhibits 1,3-beta-glucan synthase, resulting in decreased synthesis of beta(1,3)-D-glucan (an essential component ...

semanticscholar   +3 more sources

Phosphoproteomics of Aspergillus fumigatus Exposed to the Antifungal Drug Caspofungin

mSphere, 2020
Aspergillus fumigatus is an opportunistic and allergenic pathogenic fungus, responsible for fungal infections in humans. A. fumigatus infections are usually treated with polyenes, azoles, or echinocandins.
Eliciane Cevolani Mattos, Giuseppe Palmisano, Gustavo H. Goldman   +2 more
doaj   +2 more sources

Evidence supporting a role for mammalian chitinases in efficacy of caspofungin against experimental aspergillosis in immunocompromised rats. [PDF]

PLoS ONE, 2013
Caspofungin, currently used as salvage therapy for invasive pulmonary aspergillosis (IPA), strangely only causes morphological changes in fungal growth in vitro but does not inhibit the growth. In vivo it has good efficacy.
Patricia E B Verwer, Marian T ten Kate, Franco H Falcone, Shaun Morroll, Henri A Verbrugh, Irma A J M Bakker-Woudenberg, Wendy W J van de Sande   +6 more
doaj   +8 more sources

Aspergillus fumigatus Transcription Factors Involved in the Caspofungin Paradoxical Effect

mBio, 2020
Aspergillus fumigatus is the leading cause of pulmonary fungal diseases. Azoles have been used for many years as the main antifungal agents to treat and prevent invasive aspergillosis.
Clara Valero, Ana Cristina Colabardini, Jéssica Chiaratto, Lakhansing Pardeshi, Patrícia Alves de Castro, Jaire Alves Ferreira Filho, Lilian Pereira Silva, Marina Campos Rocha, Iran Malavazi, Jonas Henrique Costa, Taícia Fill, Mário Henrique Barros, Sarah Sze Wah Wong, Vishukumar Aimanianda, Koon Ho Wong, Gustavo H. Goldman   +15 more
doaj   +2 more sources

Puupehenone, a Marine-Sponge-Derived Sesquiterpene Quinone, Potentiates the Antifungal Drug Caspofungin by Disrupting Hsp90 Activity and the Cell Wall Integrity Pathway

mSphere, 2020
The cell wall-targeting echinocandin antifungals, although potent and well tolerated, are inadequate in treating fungal infections due to their narrow spectrum of activity and their propensity to induce pathogen resistance.
Siddharth K. Tripathi, Qin Feng, Li Liu, David E. Levin, Kuldeep K. Roy, Robert J. Doerksen, Scott R. Baerson, Xiaomin Shi, Xuewen Pan, Wen-Hui Xu, Xing-Cong Li, Alice M. Clark, Ameeta K. Agarwal   +12 more
doaj   +2 more sources

Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial.

The Lancet, 2022
BACKGROUND Rezafungin is a next-generation, once-a-week echinocandin in development for the treatment of candidaemia and invasive candidiasis and for the prevention of invasive fungal disease caused by Candida, Aspergillus, and Pneumocystis spp after ...
G. Thompson, Á. Soriano, O. Cornely, B. Kullberg, M. Kollef, J. Vazquez, P. Honore, M. Bassetti, J. Pullman, M. Chayakulkeeree, I. Poromanski, C. Dignani, Anita F. Das, T. Sandison, P. Pappas, M. Akova, R. AlAgha, G. Alangaden, S. Albrecht, B. Alexander, M. Al-Obaidi, G. Ambasch, F. Rodríguez, A. Azap, A. Baffoe-Bonnie, L. Belkhir, R. Ben-Ami, D. Boutoille, A. Cascio, L. Chai, R. Chaiwarith, S. Chen, Yee-Chun Chen, Yen-Hsu Chen, J. Choi, Young Hwa Choi, Darunee Chotiprasitsakul, J. Chung, F. Danion, B. Denis, E. D. Santos, M. Dictar, M. Diltoer, Hervé Dupont, S. Feng, M.A. Colomer, R. Ferrer, J. Forel, J. Fortún-Abete, J. Garcia-Diaz, M. Girardis, Fang He, M. Hites, M. Ho, P. Honore, Juan Gallego, Haihui Huang, Po-Yen Huang, Yong Huang, Osamah H. Hussein, P. Intalapaporn, S. Jaruratanasirikul, Luis Jáuregui-Peredo, Misty Johnson, D. Jung, K. Jutivorakool, W. Kern, D. Kett, T. Khawcharoenporn, Young Keun Kim, P. Koehler, A. Kotanidou, A. Lachiewicz, Qinhan Lin, Luis Eduardo López Cortés, Hong Luo, R. Luzzati, Y. Maor, T. Mccarty, M. Merelli, P. M. Amador, John K. Midturi, G. Migliorino, J. Mira, P. Mootsikapun, O. Morrissey, P. Paredes, C. Mussini, E. Mylonakis, S. Nseir, W. Nseir, Z. Odabaşı, V. Papastamopoulos, D. Paterson, T. Patterson, K. Peck, Zhiyong Peng, N. Permpalung, G. Plantefeve, I. Poromanski, D. Powell, M. Psichogiou, S. Puah, G. Rahav, A. Martínez, J. C. Ramos, A. Raz-Pasteur, Carlos Castro, F. Riera, F. Roblot, Regino Rodríguez Álvarez, B. Rogers, E. Roilides, G. Vallejo, G. Sganga, N. Sipsas, M. Slavin, A. Spec, J. Strahilevitz, D. Tancheva, Zhen Tao, D. Teschner, E. Wijngaerden, P. Vergidis, Pierluigi Viale, Fu Lee Wang, Shifu Wang, Gabriel Weber, J. Weng, Jinfu Xu, Liyuan Yao, S. Yavuz, M. Yilmaz, J. Young, Abel H Zárate, Jun Zeng, Yong Zhang   +136 more
semanticscholar   +1 more source

Efficacy and safety of rezafungin and caspofungin in candidaemia and invasive candidiasis: pooled data from two prospective randomised controlled trials.

Lancet. Infectious Diseases (Print), 2023
BACKGROUND Rezafungin, a new US Food and Drug Administration-approved, long-acting echinocandin to treat candidaemia and invasive candidiasis, was efficacious with a similar safety profile to caspofungin in clinical trials.
George R Thompson, Á. Soriano, P. Honoré, M. Bassetti, Oliver A. Cornely, Marin H. Kollef, B. Kullberg, J. Pullman, Maya Hites, Jesús Fortún, J. Horcajada, Anastasia Kotanidou, Anita F Das, T. Sandison, J. Aram, Jose A Vazquez, Peter G. Pappas   +16 more
semanticscholar   +1 more source